Bacteremia/*genetics/*mortality; Female; *Genetic Predisposition to Disease; Humans; Immunity, Innate/*genetics; *Intensive Care Units; Male; Middle Aged; *Polymorphism, Single Nucleotide
Abstract :
[en] OBJECTIVE: Critically ill patients are at risk of sepsis, organ failure, and death. Studying the impact of genetic determinants may improve our understanding of the pathophysiology and allow identification of patients who would benefit from specific treatments. Our aim was to study the influence of single nucleotide polymorphisms in selected genes involved in innate immunity on the development of bacteremia or risk of death in patients admitted to a medical intensive care unit. DESIGN, SETTING, AND PATIENTS: DNA was available from 774 medical intensive care unit patients. We selected 31 single nucleotide polymorphisms in 14 genes involved in host innate immune defense. Serum levels of MASP2 and chemotactic capacity, phagocytosis, and killing capacity of monocytes at admission were quantified. Univariate Kaplan-Meier estimates with log-rank analysis and multivariate logistic regression were performed. Bootstrap resampling technique and ten-fold cross-validation were used to assess replication stability, prognostic importance of the variables, and repeatability of the final regression model. MAIN RESULTS: Patients with at least one NOD2 variant were shown to have a reduced phagocytosis by monocytes (p = 0.03) and a higher risk of bacteremia than wild-type patients (p = 0.02). The NOD2/TLR4 combination was associated with bacteremia using survival analyses (time to bacteremia development, log-rank p < 0.0001), univariate regression (p = 0.0003), and multivariate regression analysis (odds ratio [OR] 4.26, 95% confidence interval [CI] 1.85-9.81; p = 0.0006). Similarly, the same combination was associated with hospital mortality using survival analysis (log-rank p = 0.03), univariate regression (p = 0.02), and multivariate regression analysis (OR 2.27, 95% CI 1.09-4.74; p = 0.03). Also variants in the MASP2 gene were significantly associated with hospital mortality (survival analysis log-rank-p = 0.003; univariate regression p = 0.02; multivariate regression analysis OR 2.35, 95% CI 1.38-3.99; p = 0.002). CONCLUSIONS: Functional polymorphisms in genes involved in innate immunity predispose to severe infections and death, and may become part of a risk model, allowing identification of patients at risk, who could benefit from early introduction of specific preventive or therapeutic interventions.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Henckaerts, L.
Nielsen, K. R.
Steffensen, R.
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Baue AE: MOF, MODS, and SIRS: What is in a name or an acronym? Shock 2006; 26: 438-449
Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
Teres D, Lemeshow S: Why severity models should be used with caution. Crit Care Clin 1994; 10:93-110
Sinuff T, Adhikari NKJ, Cook DJ, et al: Mortality predictions in the intensive care unit: Comparing physicians with scoring systems. Crit Care Med 2006; 34:878-885
Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock - Role in prognosis and potential for therapy. Chest 2003; 124:1103-1115
Lin MT, Albertson TE: Genomic polymorphisms in sepsis. Crit Care Med 2004; 32: 569-579
Texereau J, Pene F, Chiche JD, et al: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:S313-S319
Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
Magadia RR, Weinstein MP: Laboratory diagnosis of bacteremia and fungemia. Infect Dis Clin North Am 2001; 15:1009-1024
Bone RC, Sprung CL, Sibbald WJ: Definitions for sepsis and organ failure. Crit Care Med 1992; 20:724-726
Thiel S, Moller-Kristensen M, Jensen LI, et al: Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology 2002; 205: 446-454
Ellger G, Debaveye Y, Vanhorebeek I, et al: Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006; 55: 1096-1105
Mathieu C, Van Etten E, Gysemans C, et al: In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001; 16:2057-2065
Scheet P, Stephens M: A fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78:629-644
Barrett JC, Fry B, Mailer J, et al: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265
Netea MG, Ferwerda G, de Jong DJ, et al: Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 2005; 174:6518-6523
van Heel DA, Ghosh S, Butler M, et al: Synergistic enhancement of Toll-like receptor responses by NODI activation. Eur J Immunol 2005; 35:2471-2476
Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-3581
Stengaard-Pedersen K, Thiel S, Gadjeva M, et al: Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003; 349:554-560
Thiel S, Steffensen R, Christensen IJ, et al: Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun 2007; 8:154-163
Efron B: Bootstrap methods: Another look at the Jackknife. Ann Stat 1979; 7:1-26
Van Steen K, Curran D, Kramer J, et al: Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med 2002; 21:3865-3884
Efron B, Gong G: A leisurely look at the bootstrap, the Jackknife, and cross-validation. Am Stat 1983; 37:36-48
Mira JP, Cariou A, Grail F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
Strober W, Murray PJ, Kitani A, et al: Signalling pathways and molecular interactions of NODI and NOD2. Nat Rev Immunol 2006; 6:9-20
Hugot JP, Chamaillard M, Zouali H, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603
Ogura Y, Bonen DK, Inohara N, et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606
Henckaerts L, Vermeire S: NOD2/CARD15 disease associations other than Crohn's disease. Inflamm Bowel Dis 2007; 13:235-241
Kobayashi KS, Chamaillard M, Ogura Y, et al: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731-734
van Heel DA, Ghosh S, Butler M, et al: Murarnyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005; 365:1794-1796
Inohara N, Ogura Y, Fontalba A, et al: Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem 2003; 278:5509-5512
Bonen DK, Ogura Y, Nicolae DL, et al: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124:140-146
Barnich N, Aguirre JE, Reinecker HC, et al: Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition. J Cell Biol 2006; 170:21-26
Voss E, Wehkamp J, Wehkamp K, et al: NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006; 281:2005-2011
Wehkamp J, Harder J, Weichenthal M, et al: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1558-1560
Maeda S, Hsu IX, Liu HJ, et al: Nod2 mutation in Crohn's disease potentiates NF-kappa B activity and IL-10 processing. Science 2005; 307:734-738
Watanabe T, Kitani A, Murray PJ, et al: NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5:800-808
Doyle SL, O'Neill LAJ: Toll-like receptors: From the discovery of NFKB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006; 72: 1102-1113
Zacharowski K, Zacharowski PA, Koch A, et al: Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 2006; 103: 6392-6397
Rallabhandi P, Bell J, Boukhvalova MS, et al: Analysis of TLR4 polymorphic variants: New insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006; 177:322-332
Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2006; 25:187-191
Male D, Brostoff J, Roth D, et al: Immunology. Seventh Edition. Edinburgh, New York, Mosby, 2006
Wolfert MA, Murray TF, Boons GJ, et al: The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem 2002; 277:39179-39186
Yang S, Tamai R, Akashi S, et al: Synergistic effect of muramyldipeptide with lipopolysac-charide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 2001; 69: 2045-2053
Traub S, Kubasch N, Morath S, et al: Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction. J Biol Chem 2004; 279: 8694-8700
Brenmoehl J, Herfarth H, Glueck T, et al: Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med 2007; 33: 1541-1548
Dommett RM, Klein N, Turner MW: Mannose-binding lectin in innate immunity: Past, present and future. Tissue Antigens 2006; 68:193-209
Hansen TK, Thiel S, Wouters PJ, et al: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88:1082-1088
